Entity family
Named medicines, compounds, vaccines, and pharmacological agents. Examples include metformin, semaglutide, antibiotics.
This drug is selected. Its supporting articles are shown below.
…therapy), and 18 months of adjuvant therapy with relugolix plus enzalutamide. Primary outcomes include pathologic CR rate and minimal residu…
…progression, persistence, or recurrence and were candidates for piflufolastat PET per Central Pharmacy and Therapeutics Commission protocol. …
…, Gravis G, et al. Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patient…
…ion-level assessment.86 Similarly, 177Lu-DOTATATE combined with nivolumab has shown tolerability and preliminary activity in pulmonary ne…
… inhibitor olaparib in combination with the anti-PD-L1 antibody durvalumab in an HRR-unselected population of men with metastatic castrati…
…eceived abiraterone, 31% apalutamide, 26% enzalutamide, and 11% docetaxel. Median PFS and OS were 32 and 50 months, respectively, in the …
…metastatic hormone-sensitive prostate cancer (mHSPC) (ARASENS). Darolutamide was commercialised in 2020.Aim and Objectives To evaluate the t…
…Results Of 88 patients (mean age 76.9 ± 8.2 years), 70 received abiraterone, 8 apalutamide, six enzalutamide, three darolutamide, and one o…
… 5% had ovarian, renal or lung cancer. The involved drugs were: enzalutamide(25), apalutamide(14), abiraterone (9), abemaciclib(6), capecita…